

## Amethyst Service Operations

### 1. Background and Introduction

- 1.1 Amethyst Radiotherapy Group BV (“Amethyst”) is a registered company at Strawinskylaan, 3127 Atrium 8EV, 1077 Amsterdam, the Netherlands; registration number NL76143236.
- 1.2 Amethyst was founded in 2010 to deliver next generation (*non surgical*) Oncology treatments to address the legacy demand and supply deficit (*both quantitative and qualitative*) across the international Cancer Care market. From its first greenfield Centre build in Bucharest in 2010, Amethyst has expanded with further greenfield Centre developments across Austria, Poland and Romania, outsourcing of Radiotherapy (RT) wards in Italy, and Centre acquisitions in France and UK. Amethyst now operates 15 specialist Cancer Treatment Centres, comprising 25 Linear Accelerators (Linacs) and two GammaKnife Radiosurgery treatment systems across six countries:
  - France
  - Romania
  - UK
  - Poland
  - Italy
  - Austria
- 1.3 Amethyst is the largest provider of RT services in Europe treating over 20,000 patients a year. It operates some of the highest volume Linear Accelerators (*Linacs*) in Europe, with 220 patients a day treated in its high-volume centres; equivalent to +70 patients per Linac per day; bringing treatment times to eight minutes per treatment fraction. This is double the typical Linac utilisation to be found in any government operated RT Centre anywhere. Amethyst employs over 550 clinical and administrative staff across the Group.
- 1.4 Amethyst is privately owned by its founders, Ludovic Robert (*CEO*) and Avner Goldenberg (*Chairman*), both with a proven track record over 35 years of creating and growing market leading healthcare and pharmaceutical companies. In October 2019, a specialist New York based investment fund, The Rohatyn Group <https://www.rohatyngroup.com/> acquired a 28% equity holding in Amethyst with the aim of supporting further growth.
- 1.5 Amethyst was one of the first operators to deploy cutting edge radiation techniques such as Intensity Modulated Radiotherapy (IMRT), Volumetric Modulated Arc Therapy (VMAT) and Image Guided Radiotherapy (IGRT) at a time when government systems across the world were typically still using old 3D conformal radiation technology. These new techniques deliver more precisely targeted radiation treatment to patients with vastly improved outcomes sparing less damage to healthy tissues and organs at risk.
- 1.6 Amethyst strives to evolve and enhance its established leadership position in the delivery of radiation and oncology techniques with the recent move towards delivering Stereotactic Radiotherapy for precise irradiation of image defined lesions; using higher radiation doses delivered in smaller numbers of fractions to more precisely target the tumour. The technique spares the surrounding healthy normal tissues; lowering the risk of side effects and reducing the required number of treatments per patient episode.

- 1.7 Adapting quickly to new techniques ensured Amethyst could successfully navigate service restrictions during the Covid pandemic; and now post pandemic the crisis in Cancer Care presents a material opportunity for Amethyst over the next 3-5 years.
- 1.8 Amethyst operates its Treatment Centres to the highest quality standards, underpinned with robust clinical governance and exceptional focus on patient experience and treatment outcomes. It achieves this by working in partnership with leading University Teaching Hospitals (*including but not limited to*):
  - Institut Curie, France
  - Institut Gustave Roussy, France
  - Freiburg and Wurzburg Universitie, Germany
  - UZ Brussel, Belgium
  - UCLH, UK
  - Sheffield Teaching Hospitals NHS FT, UK
- 1.9 Amethyst's Medical Board comprises some of the foremost expert Oncologists in the international field, providing strong clinical oversight and governance across the Group's Centers. The Board currently comprises:
  - Prof. Nick Plowman, Bart's and the London University Teaching Hospitals
  - Prof. Jean March Cosset, Marie Curie Institut, Paris, France
  - Dr Christine Haie-Meder, Institut Gustav Roussy, Paris, France
  - Professor Guy Storme, University Hospital Brussels/UZ Brussel, Belgium
  - Professor Chiricuta, Wurzburg University Hospitals, Germany

## 2. Amethyst UK

- 2.1 Amethyst entered the UK healthcare market in March 2020 with the acquisition of two leading Radiosurgery Centres in London and Sheffield.
- 2.2 Amethyst operates a specialist Intracranial Stereotactic Radiosurgery Service for the treatment of inoperable brain tumours in adults, on behalf of University College Hospital's NHS Trust's (UCLH) National Hospital for Neurology and Neurosciences; a world-renowned clinical research, teaching and tertiary service Centre of Excellence, recently named one of the top three leading Neurosciences Centres in the world by Newsweek.
- 2.3 Amethyst also operates a paediatric brain tumour radiosurgery service in collaboration with Great Ormond Street Hospital for Children NHS Trust.
- 2.4 Amethyst's collaboration with ULCH is one of only two such national Centres of Excellence approved by NHS England; the other being the National Stereotactic Radiosurgery Centre at the Royal Hallamshire Hospital, Sheffield where Amethyst also provides a Service in collaboration with Sheffield NHS
- 2.5 NHS patient activity currently accounts for +80% of Amethyst's UK patient throughput funded under longterm evergreen contracts with UCLH, Sheffield NHS and NHS England.
- 2.6 Amethyst is now scaling up its UK Service Operations given the post Covid operating landscape where Cancer Care is one of the top UK health priorities. This includes (*but not limited to*):
  - new £20m greenfield Treatment Centre "*Design and Build*" project in Glasgow working in partnership with the Beatson Oncologists, scheduled for opening in Q1 2024 (*one of only five standalone Cancer Hospitals in the UK*)



# Amethyst

RADIOTHERAPY

Office 16  
44 Russell Square  
London WC1B 4JP

- new +£50m “*Design and Build*” specialist Cancer Centre in collaboration with Sheffield’s Weston Park Cancer Hospital
- £20m upgrade to existing London Radiosurgery Service Centre

---

+44 (0) 20 3941 6395

[contactme@amethyst-radiotherapy.co.uk](mailto:contactme@amethyst-radiotherapy.co.uk)

[www.amethyst-radiotherapy.co.uk](http://www.amethyst-radiotherapy.co.uk)